GALECTIN THERAPEUTICS INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $14.3M | $36.6M | $32.1M | $31.7M | $23.8M | $18.0M | $7.5M |
| SG&A Expense | — | $5.8M | $5.9M | $5.9M | $6.6M | $6.4M | $5.5M | $6.0M |
| Operating Income | — | $-20.1M | $-42.4M | $-38.1M | $-38.4M | $-30.2M | $-23.4M | $-13.4M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | $2.8M | $1.0M | $489.0K | $87.0K | $87.0K |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | $0 | — | — | — | — | — |
| Net Income | — | $-30.8M | $-47.0M | $-41.1M | $-38.8M | $-30.5M | $-23.5M | $-13.3M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-0.48 | $-0.76 | $-0.74 | $-0.65 | $-0.52 | $-0.41 | $-0.39 |
| EPS (Diluted) | — | $-0.48 | $-0.76 | $-0.74 | $-0.65 | $-0.52 | $-0.41 | $-0.39 |
| Shares Outstanding (Basic) | 65.8M | 63.9M | 62.3M | 60.2M | 59.4M | 58.5M | 57.0M | 56.9M |
| Shares Outstanding (Diluted) | 65.8M | 63.9M | 62.3M | 60.2M | 59.4M | 58.5M | 57.0M | 56.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |